Journal article icon

Journal article

Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis

Abstract:
Objective To assess the frequency of cardiovascular and venous thromboembolic events in clinical studies of baricitinib, an oral, selective JAK1 and JAK2 inhibitor approved in more than 50 countries for the treatment of moderately‐to‐severely active rheumatoid arthritis (RA). Methods Data were pooled from 9 RA studies. Placebo comparison up to 24 weeks included data from 6 studies. Randomized dose comparison between baricitinib doses of 2 mg and 4 mg used da... Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1002/art.40841

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDORMS
Oxford college:
St Peter's College
Role:
Author
ORCID:
0000-0001-7766-6167
Publisher:
Wiley
Journal:
Arthritis and Rheumatology More from this journal
Volume:
71
Issue:
7
Pages:
1042-1055
Publication date:
2019-05-25
Acceptance date:
2019-01-09
DOI:
ISSN:
2326-5191 and 2326-5205
Pubs id:
pubs:966774
UUID:
uuid:09351b02-edc9-4deb-9996-14f2a06d8569
Local pid:
pubs:966774
Source identifiers:
966774
Deposit date:
2019-01-29

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP